> FILE REG

FILE 'REGISTRY' ENTERED AT 17:21:41 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2010 HIGHEST RN 1233453-03-6
DICTIONARY FILE UPDATES: 21 JUL 2010 HIGHEST RN 1233453-03-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading 10588166.str



chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-12 4-11 6-7 7-8 7-9 7-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-12 2-3 3-4 4-5 4-11 5-6 6-7 7-8 7-9 7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS

Uploading LL5.str




```
chain nodes :
7  8  9  10  11  12
ring nodes :
1  2  3  4  5  6
chain bonds :
1-12  4-11  6-7  7-8  7-9  7-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-12  4-11  6-7
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-9  7-10


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS
```

AUTHOR SEARCH

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 17:21:44 ON 22 JUL 2010

FILE COVERS 1907 - 22 Jul 2010 VOL 153 ISS 4
FILE LAST UPDATED: 21 Jul 2010 (20100721/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

```
http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L33
L24        2346 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L25         205 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L26          71 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L27        2879 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L28           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L33           5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L24 AND ((L25 OR L26
                OR L27 OR L28))


=> FILE WPIX
FILE 'WPIX' ENTERED AT 17:21:54 ON 22 JUL 2010
COPYRIGHT (C) 2010 THOMSON REUTERS

FILE LAST UPDATED:          21 JUL 2010   <20100721/UP>
MOST RECENT UPDATE:           201046      <201046/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.6 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
    and FI-Terms have been updated with reclassifications to
    end of March 2010.
    No update date (UP) has been created for the reclassified
    documents, but they can be identified by
    specific update codes (see HELP CLA for details) <<<

>>> FOR THE LATEST DERWENT WORLD PATENTS INDEX (DWPI)
    STN USER DOCUMENTATION, PLEASE VISIT:
    http://www.stn-international.com/stn_dwpi.html <<<

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> For changes in DWPI see HELP CHANGE - last updated April 6, 2010 <<<

>>> New display format ALLSTR available - see NEWS  <<<

>>> US National Patent Classification thesaurus added - see NEWS <<<

=> D STAT QUE L52
L41         113 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L42          21 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L43          13 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L44         142 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L45           8 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L48           2 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L41 AND ((L42 OR L43 OR
                L44 OR L45))
L49           1 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L42 AND ((L43 OR L44 OR
                L45))
L50           1 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L43 AND ((L44 OR L45))
L52           2 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50)


=> DUP REMOVE L33 L52
FILE 'HCAPLUS' ENTERED AT 17:22:10 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

FILE 'WPIX' ENTERED AT 17:22:10 ON 22 JUL 2010

PROCESSING COMPLETED FOR L33
PROCESSING COMPLETED FOR L52
L60 7 DUP REMOVE L33 L52 (0 DUPLICATES REMOVED)
ANSWERS '1-5' FROM FILE HCAPLUS
ANSWERS '6-7' FROM FILE WPIX

=> D L60 IBIB ABS HITIND HITSTR 1-5; D L60 IBIB AB HITSTR 6-7

L60 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:331043 HCAPLUS Full-text
DOCUMENT NUMBER: 148:547206
TITLE: Synthesis and structural characteristics of highly graphitized carbon nanofibers produced from the catalytic decomposition of ethylene: Influence of the active metal (Co, Ni, Fe) and the zeolite type support
AUTHOR(S): Romero, Amaya; Garrido, Agustin; Nieto-Marquez, Antonio; Sanchez, Paula; de Lucas, Antonio; Valverde, Jose Luis
CORPORATE SOURCE: Facultad de Ciencias Quimicas/Escuela Tecnica Agricola, Universidad de Castilla-La Mancha, Ciudad Real, 13071, Spain
SOURCE: Microporous and Mesoporous Materials (2008), 110(2-3), 318-329
CODEN: MIMMFJ; ISSN: 1387-1811
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In order to study the influence of the metal phase in the carbon yield and structural characteristics of carbon nanofibers (CNFs) synthesized by CVD over supported catalysts, different catalysts were prepared using iron, cobalt and nickel as active metal and zeolites Y and mordenite as support. The results showed that the metal precursor produced a great influence on the catalytic activity, fact that could be explained in according to the different solubility of carbon in the metals or in the differences in the diffusion and segregation of carbon through the metal particles. Characterization data of the solid carbon products revealed unique structures and textural properties as well as crystalline conditions on function of metal used. Addnl., support-metal interaction was evaluated, where expts. with similar nickel load over Y and mordenite zeolites were carried out, finding higher carbon yields and more ordered structures when Y zeolite was used.

CC 67-3 (Catalysis, Reaction Kinetics, and Inorganic Reaction Mechanisms)
Section cross-reference(s): 66, 75
OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1032532 HCAPLUS Full-text
DOCUMENT NUMBER: 143:464206
TITLE: Growth of Carbon Nanofibers from Ni/Y Zeolite Based Catalysts: Effects of Ni Introduction Method, Reaction Temperature, and Reaction Gas Composition
AUTHOR(S): de Lucas, Antonio; Garrido, Agustin; Sanchez, Paula; Romero, Amaya; Valverde, Jose L.
CORPORATE SOURCE: acultad de Ciencias Quimicas y Escuela Tecnica

```
                          Agricola, Departamento de Ingenieria Quimica,
                          Universidad de Castilla La Mancha, Ciudad Real, 13071,
                          Spain
SOURCE:                   Industrial & Engineering Chemistry Research (2005),
                          44(22), 8225-8236
                          CODEN: IECRED; ISSN: 0888-5885
PUBLISHER:                American Chemical Society
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
```

AB Results of thorough studies of the catalytic synthesis of carbon nanofibers (CNFs) by the decomposition of ethylene using Y zeolite as the support and Ni as the active phase were discussed. Exptl. results clearly indicated that the metal-incorporation method (ion exchange or impregnation) had very significant effects not only on CNFs growth but also on the deactivation rate, the final yield of CNFs, and the characteristics of the synthesized CNFs. CNFs synthesized from the impregnated catalyst grew from small and well-dispersed Ni particles anchored to the outer surface of the zeolite. Nevertheless, CNFs synthesized from the ion-exchanged catalyst grew from Ni particles (of very small size) lodged inside the pore system of the zeolite. Reaction temperature and C_2H_4/H_2 (volume/volume) had a considerable effect on both carbon yield and CNFs morphol. Two types of CNFs were observed as a function of the reaction temperature: "fishbone structures" at temps. below 600° C and "tubular structures" at temps. above 600° C. On the other hand, as the C_2H_4/H_2 ratio was decreased, the CNFs became slightly more graphitic in nature and the arrangement of graphite sheets changed from the fishbone structure to "octopus carbon".

```
CC   57-8 (Ceramics)
     Section cross-reference(s): 78
OS.CITING REF COUNT:      12    THERE ARE 12 CAPLUS RECORDS THAT CITE THIS
                                RECORD (12 CITINGS)
REFERENCE COUNT:          63    THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60  ANSWER 3 OF 7  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2003:347304  HCAPLUS  Full-text
DOCUMENT NUMBER:          139:56904
TITLE:                    Characterization and Catalytic Properties of
                          Titanium-Pillared Clays Prepared at Laboratory and
                          Pilot Scales: A Comparative Study
AUTHOR(S):                Valverde, Jose L.; De Lucas, Antonio; Dorado,
                          Fernando; Sun-Kou, Rosario; Sanchez, Paula;
                          Asencio, Isaac; Garrido, Agustin; Romero,
                          Amaya
CORPORATE SOURCE:         Departamento de Ingenieria Quimica Facultad de
                          Quimicas, Universidad de Castilla-La Mancha, Ciudad
                          Real, 13004, Spain
SOURCE:                   Industrial & Engineering Chemistry Research (2003),
                          42(12), 2783-2790
                          CODEN: IECRED; ISSN: 0888-5885
PUBLISHER:                American Chemical Society
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
```

AB The textural and structural characteristics and the acid properties of Ti-pillared montmorillonites prepared at bench scale (1 kg per batch level) have been compared with those prepared at laboratory scale (a few grams). The pillared clays have been examined by X-ray diffraction and characterized by different techniques and methods including nitrogen sorption isotherms, temperature-programmed desorption/reduction, and atomic absorption. The catalytic performance was evaluated by means of the selective reduction of NO by propylene over Cu^{2+} ion-exchanged samples. The differences of the textural characteristics between the laboratory and pilot samples did not significantly affect the catalytic results.

CC 59-3 (Air Pollution and Industrial Hygiene)

```
     Section cross-reference(s): 67
OS.CITING REF COUNT:      5     THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
                                (6 CITINGS)
REFERENCE COUNT:          57    THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60  ANSWER 4 OF 7  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2001:29927  HCAPLUS  Full-text
DOCUMENT NUMBER:          134:265289
TITLE:                    Quality of olive oil. III. Application of
                          near-infrared spectroscopy (NIRS) to the quality
                          control of olive oil
AUTHOR(S):                Garrido, A.; Sanchez Pineda de las
                          Infantas, M. T.; Cobo, C.
CORPORATE SOURCE:         Depto. de Produccion Animal, Univ. de Cordoba, Spain
SOURCE:                   Alimentacion, Equipos y Tecnologia (2000), 19(7),
                          165-170
                          CODEN: AEQTDY; ISSN: 0212-1689
PUBLISHER:                Editorial Alcion, S.A.
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 Spanish
AB    A review with 41 refs.  The topics include current status of olive oil anal. and
      quality control, principles and instrumentation of NIRS, qual. and quant. anal. of
      olive oil by NIRS, and broader anal. applications to the anal. of oils and fats.
CC    17-0 (Food and Feed Chemistry)
REFERENCE COUNT:          41    THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60  ANSWER 5 OF 7  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2000:556213  HCAPLUS  Full-text
DOCUMENT NUMBER:          134:70432
TITLE:                    Olive oil quality. I. Concepts and analytical and
                          sensorial parameters of quality
AUTHOR(S):                Sanchez Pineda, M. T.; Garrido, A.
                          ; Cobo, C.
CORPORATE SOURCE:         Dpt. de Bromatologia y Tecnologia de los Alimentos,
                          Universidad de Cordoba, Spain
SOURCE:                   Alimentacion, Equipos y Tecnologia (2000), 19(5),
                          63-69
                          CODEN: AEQTDY; ISSN: 0212-1689
PUBLISHER:                Editorial Alcion, S.A.
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 Spanish
AB    A review with 21 refs. on the concept of olive oil quality, parameters of oil
      quality determined by traditional physicochem. methods, and olive oil quality
      parameters determined by organoleptic anal.
CC    17-0 (Food and Feed Chemistry)
REFERENCE COUNT:          21    THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L60  ANSWER 6 OF 7  WPIX COPYRIGHT 2010       THOMSON REUTERS on STN
ACCESSION NUMBER:      2008-D99595 [200828]   WPIX
CROSS REFERENCE:       2008-E49165; 2008-E61270; 2008-G33820; 2008-L13777
DOC. NO. CPI:          C2008-131560 [200828]
TITLE:                 Use of dihydroxybenzene compound to treat e.g.
                       hemangiomas, hemangioblastomas, benign prostatic
                       hyperplasia, Barrett's disease, asthma, skeletal muscle
                       and tendon repair, Crohn's disease, ulcerative colitis
```

and leishmaniasis
DERWENT CLASS: B05
INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S; LOPEZ S V; FERNANDEZ JAEN T F; FRUTOS J A; MORENO NUNCIO F J; RIVAS LOPEZ L I; SANCHEZ P C
PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
COUNTRY COUNT: 120

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020034	A1	20080221	(200828)*	EN	101[22]	
US 20080114063	A1	20080515	(200835)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020034	A1	WO 2007-EP58447	20070815
US 20080114063	A1	US 2007-839529	20070815

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816

AB WO 2008020034 A1 UPAB: 20080501

NOVELTY - Use of a 2,5-dihydroxybenzene compound (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.

DETAILED DESCRIPTION - Use of a 2,5-dihydroxybenzene compound of formula (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.

R1 = -(CH2)aY1 or -CH=CH-(CH2)pY1;

Y1 = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ or -CO2R3;

X+ = organic cation or inorganic cation such that general charge of (I) is neutral;

R9, R9a = -OH or -OR2;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R3 = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

ACTIVITY - Cytostatic; Gastrointestinal-Gen; Antiinflammatory; Antiasthmatic; Muscular-Gen; Osteopathic; Antiulcer; Protozoacide; Analgesic; Antiarthritic.

MECHANISM OF ACTION - None given.

USE - (I) is useful for treating/preventing a disease of hemangiomas and hemangioblastomas (claimed), benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis and pancolitis), leishmaniasis, pain and arthritis. The ability of (I) to treat muscle lesion was tested in a patient. The result showed that the patient (taken 500 mg of 2,5-dihydroxybenzene sulfonic acid for two weeks) recovered from the lesion in the quadriceps and the hematoma was not observed.

ADVANTAGE - (I) is safe and effective for treating leishmaniasis. (I) exhibits pharmacological properties.

L60 ANSWER 7 OF 7 WPIX COPYRIGHT 2010 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-F85649 [200837] WPIX
CROSS REFERENCE: 2008-G33818; 2008-G33819; 2008-G33821; 2008-L13776

DOC. NO. CPI: C2008-188857 [200837]
TITLE: Use of 2,5-dihydroxybenzene derivatives to prepare a medicament for the therapeutic and/or prophylactic treatment of e.g. skin cancer, prostate cancer, thyroid cancer, hematological dyscrasias and fibrosis (e.g. endomyocardial fibrosis)
DERWENT CLASS: B05
INVENTOR: ROMERO GARRIDO A; ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; MORGAN I S D T; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; SAENZ DE TEJADA MORGAN I; VALVERDE LOPEZ S; VAVERDE LOPEZ S; DE TEJADA M I S; FRUTOS J A; GALLEGO G G; GARRIDO A R; LOPEZ S V; LOZANO P R M; SANCHEZ P C
PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL; (ACTI-N) ACTION MEDICINES
COUNTRY COUNT: 120

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020027	A2	20080221	(200837)*	EN	86[15]	
US 20080113947	A1	20080515	(200837)	EN		
US 20080113948	A1	20080515	(200837)	EN		
US 20080114060	A1	20080515	(200837)	EN		
WO 2008020027	A3	20080410	(200837)	EN		
US 20080125486	A1	20080529	(200838)	EN		
ES 2315118	A1	20090316	(200922)	ES		
ES 2315118	B1	20091230	(201004)	ES		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020027	A2	WO 2007-EP58440	20070815
ES 2315118	A1	ES 2006-2218	20060816
US 20080113947	A1	US 2007-839515	20070815
US 20080113948	A1	US 2007-839520	20070815
US 20080114060	A1	US 2007-839522	20070815
US 20080125486	A1	US 2007-839525	20070815
ES 2315118	B1	ES 2006-2218	20060816

PRIORITY APPLN. INFO: ES 2007-1856 20070702
ES 2006-2218 20060816

AB WO 2008020027 A2 UPAB: 20090407

NOVELTY - Use of 2,5-dihydroxybenzene derivatives (I) and their salts, solvate, isomer or prodrug to prepare a medicament for the therapeutic and/or prophylactic treatment of skin cancer, is claimed.

DETAILED DESCRIPTION - Use of a 2,5-dihydroxybenzene derivatives of formula (I) and their salts, solvate, isomer or prodrug to prepare a medicament for the therapeutic and/or prophylactic treatment of skin cancer, is claimed.

R1 = -(CH2)aY1 or -CH=CH-(CH2)pZ;

Y1 = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3;

Z = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ or -CO2R3;

X+ = organic cation or inorganic cation, such that the general charge of the compound is neutral;

R9, R9a = OH or OR2;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R3 = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

Provided that: when Y1 is -SO3H, -SO3-.X+ or -SO3R3, then R9, R9a are OH or OR2; at least one of R9, R9a is alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted); and when R9, R9a are both OR2, then R9, R9a can be the same or different.

ACTIVITY - Cytostatic; Antianemic; Immunostimulant; Antiinflammatory.

MECHANISM OF ACTION - Fibroblast mitogenesis inhibitor.

USE - (I) are useful to treat skin cancer such as lentigo maligna, melanoma, keratoacanthoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, sarcoma, angiosarcoma, cutaneous lymphoma, sweat gland carcinoma and sebaceous gland carcinoma (claimed). (I) are useful to treat hematological dyscrasias, myelodysplastic syndromes or fibrosis (e.g. endomyocardial fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis, progressive massive fibrosis and renal interstitial fibrosis). (I) are useful for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. (I) is useful for the treatment/prophylaxis of cancer of an organ (e.g. breast cancer, bladder cancer, colon cancer, rectal cancer, kidney cancer, lung cancer, cervical cancer, prostate cancer, brain cancer, testicular cancer, thyroid cancer and ovarian cancer). The ability of (I) to treat prostate cancer was tested in mice. The result showed that the percentage of control of prostate cancer by 2,5-diacetoxybenzene sulfonate was 85% and 72%, at 1 mu M and 5 mu M, respectively.

ADVANTAGE - (I) are effective for treating fibrosis and cancer.

STRUCTURE SEARCH

=> FILE HCAPLUS

```
FILE 'HCAPLUS' ENTERED AT 17:22:51 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

=> D STAT QUE L23

```
L2               STR
```




```
NODE ATTRIBUTES:
HCOUNT  IS M1     AT  10
HCOUNT  IS M1     AT  11
HCOUNT  IS M1     AT  12
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   7  8  9 10 11 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L4          575 SEA FILE=REGISTRY SSS FUL L2
L5               STR
```




```
NODE ATTRIBUTES:
HCOUNT  IS M1     AT  10
HCOUNT  IS M1     AT  11
HCOUNT  IS M1     AT  12
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   7  8  9 10 11 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L7           569 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L8          1313 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L7
L9         21558 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT/CT OR
                 (?PSORIASIS? OR ?PUSTULOSIS?)/BI
L10            6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L8 AND L9
L11          553 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L8 AND ((BAC OR DMA
                 OR PAC OR PKT OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR
                 ?TREAT?)/BI)
L12            6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L11 AND L9
L13            6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L10 OR L12
L14            1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "2,5-DIHYDROXYBENZENE
                 SULFONIC ACID"/CN
L15          181 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L14
L16           68 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND ((BAC OR DMA
```

```
                OR PAC OR PKT OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR
                ?TREAT?)/BI)
L17           5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L16 AND L9
L18           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L13 OR L17
L19           4 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  ("2,5-DIHYDROXYBENZEN
                ESULFONIC ACID CALCIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONI
                C ACID DIETHYLAMINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC
                ACID MONOSODIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                MONOTOSYLATE MORPHOLINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFON
                IC ACID SODIUM SALT"/CN)
L20         494 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L19
L21         359 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L20 AND ((BAC OR DMA
                OR PAC OR PKT OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR
                ?TREAT?)/BI)
L22           4 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L21 AND L9
L23           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L22 OR L18


=> S L23 NOT L33
L61           6 L23 NOT L33

=> FILE WPIX
FILE 'WPIX' ENTERED AT 17:23:02 ON 22 JUL 2010
COPYRIGHT (C) 2010 THOMSON REUTERS

FILE LAST UPDATED:          21 JUL 2010   <20100721/UP>
MOST RECENT UPDATE:           201046      <201046/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.6 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
    and FI-Terms have been updated with reclassifications to
    end of March 2010.
    No update date (UP) has been created for the reclassified
    documents, but they can be identified by
    specific update codes (see HELP CLA for details) <<<

=> D STAT QUE L40
L5              STR
```



```
NODE ATTRIBUTES:
HCOUNT  IS M1      AT  10
HCOUNT  IS M1      AT  11
HCOUNT  IS M1      AT  12
NSPEC   IS R       AT   1
NSPEC   IS R       AT   2
NSPEC   IS R       AT   3
NSPEC   IS R       AT   4
NSPEC   IS R       AT   5
NSPEC   IS R       AT   6
NSPEC   IS C       AT   7
NSPEC   IS C       AT   8
NSPEC   IS C       AT   9
NSPEC   IS C       AT  10
NSPEC   IS C       AT  11
NSPEC   IS C       AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS   AT   7  8  9 10 11 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L38           31 SEA FILE=WPIX SSS FUL L5
L39           99 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L38/DCR
L40            4 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L39 AND (?PSORIASIS? OR
                ?PUSTULOSIS?)


=> S L40 NOT L52
L62           4 L40 NOT L52

=> DUP REMOVE L61 L62
FILE 'HCAPLUS' ENTERED AT 17:23:38 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 17:23:38 ON 22 JUL 2010
COPYRIGHT (C) 2010 THOMSON REUTERS
PROCESSING COMPLETED FOR L61
PROCESSING COMPLETED FOR L62
L63            8 DUP REMOVE L61 L62 (2 DUPLICATES REMOVED)
                ANSWERS '1-6' FROM FILE HCAPLUS
                ANSWERS '7-8' FROM FILE WPIX

L63  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2010 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2008:221788  HCAPLUS  Full-text
DOCUMENT NUMBER:          148:276732
TITLE:                    Use of 2,5-dihydroxybenzene derivatives for the
                          treatment of arthritis and pain
INVENTOR(S):              Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo;
                          Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier;
                          Lozano Puerto, Rosa Maria; Romero Garrido, Antonio;
                          Valverde Lopez, Serafin
PATENT ASSIGNEE(S):       Action Medicines, S.L., Spain
SOURCE:                   PCT Int. Appl., 134pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
```

```
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  5
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.       DATE
     ---------------     ----   --------   --------------------  --------
     WO 2008020033        A1    20080221   WO 2007-EP58446       20070815
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
     ES 2315117           A1    20090316   ES 2006-2217          20060816
     ES 2315117           B1    20091230
     US 20080114063       A1    20080515   US 2007-839529        20070815
     EP 2054045           A1    20090506   EP 2007-788431        20070815
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
             AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.:                     ES 2006-2217       A  20060816
                                           ES 2007-1855       A  20070702
                                           WO 2007-EP58446    W  20070815
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):         MARPAT 148:276732
AB    The present invention relates to the use of 2,5-dihydroxybenzene derivs. or
pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the
manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.
IPCI A61K0031-10 [I,A]; A61K0031-095 [I,C*]; A61K0031-192 [I,A]; A61K0031-185
     [I,C*]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61K0031-618 [I,A];
     A61K0031-60 [I,A]
IPCR A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]; A61K0031-192
     [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-618 [I,A];
     A61P0019-00 [I,C]; A61P0019-02 [I,A]
CC   1-7 (Pharmacology)
     Section cross-reference(s): 63
ST   hydroxybenzene deriv arthritis pain therapy
IT   Hepatocyte growth factor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (antagonists; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Angiogenesis
        (corneal; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Blood vessel, neoplasm
        (hemangioblastoma; use of hydroxybenzene derivs. for treatment
        of arthritis and pain)
IT   Respiratory system disease
        (hyperresponsiveness; use of hydroxybenzene derivs. for
        treatment of arthritis and pain)
IT   Helicobacter pylori
        (infection; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Pharmaceutical injections
        (intraarticular; use of hydroxybenzene derivs. for treatment
```

```
        of arthritis and pain)
IT   Protozoacides
        (leishmanicides; use of hydroxybenzene derivs. for treatment
        of arthritis and pain)
IT   Skeletal muscle
        (lesions; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Arthritis
        (lupus-related, psoriasis-related, infectious, viral,
        parasitic, bacterial; use of hydroxybenzene derivs. for
        treatment of arthritis and pain)
IT   Fibroblast
        (mitogenesis; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Leukotrienes
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (modifiers; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Arthritis
        (polyarthritis; use of hydroxybenzene derivs. for treatment
        of arthritis and pain)
IT   Disease, animal
        (pterygium; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Proliferation inhibition
        (retinal endothelial; use of hydroxybenzene derivs. for
        treatment of arthritis and pain)
IT   Interleukin receptors
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (solubilized; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   Pharmaceutical emulsions
     Topical drug delivery systems
        (topical lotions; use of hydroxybenzene derivs. for treatment
        of arthritis and pain)
IT   Analgesics
     Anesthetics
     Angiogenesis inhibitors
     Anti-inflammatory agents
     Antiandrogens
     Antiarthritics
     Antiasthmatics
     Antibiotics
     Antioxidants
     Antirheumatic agents
     Antitumor agents
     Asthma
     Buccal drug delivery systems
     Cholinergic antagonists
     Crohn disease
     Endometriosis
     Gastroenteritis
     Gout
     Hemangioma
     Human
     Immunomodulators
     Immunosuppressants
     Inhalation drug delivery systems
     Leishmaniasis
     Neuroglia, neoplasm
```

```
     Nonsteroidal anti-inflammatory drugs
     Ophthalmic drug delivery systems
     Oral drug delivery systems
     Osteoarthritis
     Otic drug delivery systems
     Pain
     Parasiticides
     Parenteral drug delivery systems
       Pharmaceutical creams
       Pharmaceutical gels
       Pharmaceutical solids
       Pharmaceutical solutions
       Prodrugs
     Prophylaxis
     Rectal drug delivery systems
     Rheumatoid arthritis
     Topical drug delivery systems
     Transdermal drug delivery systems
     Ulcerative colitis
     Vaginal drug delivery systems
     α-Adrenoceptor antagonists
     β-Adrenoceptor agonists
        (use of hydroxybenzene derivs. for treatment of arthritis and
        pain)
IT   Corticosteroids
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (use of hydroxybenzene derivs. for treatment of arthritis and
        pain)
IT   62031-54-3, Fibroblast growth factor   62229-50-9, Epidermal growth factor
     127464-60-2, Vascular endothelial growth factor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (antagonists; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   7440-57-5, Gold, biological studies
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (i.m.; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   9081-34-9, 5-α-Reductase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitors; use of hydroxybenzene derivs. for treatment of
        arthritis and pain)
IT   106096-92-8, FGF-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (use of hydroxybenzene derivs. for treatment of arthritis and
        pain)
IT   88-46-0, 2,5-Dihydroxybenzenesulfonic acid   88-46-0D,
     2,5-Dihydroxybenzenesulfonic acid, ester derivs.   636-01-1,
     2,5-Dihydroxycinnamic acid   21799-87-1, Potassium
     2,5-dihydroxybenzenesulfonate   28088-64-4D, Aminosalicylic acid, derivs.
     51579-69-2   57775-26-5   59687-22-8   60630-38-8   63177-57-1
     79122-68-2   159252-66-1   159252-66-1D, ester derivs.   748106-93-6
     1007839-71-5   1007839-72-6D, ester derivs.   1007839-87-3   1007839-89-5
     1007839-91-9   1007839-93-1   1007839-94-2   1007839-96-4   1007840-16-5
     1007840-17-6   1007840-18-7   1007840-19-8   1007840-20-1   1007840-21-2
     1007840-22-3   1007840-23-4   1007840-24-5   1007849-27-5
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (use of hydroxybenzene derivs. for treatment of arthritis and
```

```
        pain)
IT   88-46-0, 2,5-Dihydroxybenzenesulfonic acid   88-46-0D,
     2,5-Dihydroxybenzenesulfonic acid, ester derivs.   21799-87-1,
     Potassium 2,5-dihydroxybenzenesulfonate
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (use of hydroxybenzene derivs. for treatment of arthritis and
        pain)
RN   88-46-0  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-  (CA INDEX NAME)
```



```
RN   88-46-0  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-  (CA INDEX NAME)
```



```
RN   21799-87-1  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1)  (CA INDEX
     NAME)
```



```
REFERENCE COUNT:         6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63  ANSWER 2 OF 8  HCAPLUS  COPYRIGHT 2010 ACS on STN DUPLICATE 2
ACCESSION NUMBER:        2005:888919  HCAPLUS  Full-text
DOCUMENT NUMBER:         143:216719
TITLE:                   Use of 2,5-dihydroxybenzenesulfonic acid in the
                         production of medicaments for the treatment
```

of angiodependent diseases such as cancer and psoriasis

INVENTOR(S): Cuevas, Sanchez Pedro
PATENT ASSIGNEE(S): Investread Europa, S.L., Spain
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

```
     PATENT NO.          KIND   DATE       APPLICATION NO.       DATE
     ---------------     ----   --------   --------------------  --------
     WO 2005077352        A1    20050825   WO 2005-ES70017       20050216
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     ES 2238924           A1    20050901   ES 2004-371           20040217
     ES 2238924           B1    20061201
     AU 2005211956        A1    20050825   AU 2005-211956        20050216
     CA 2555248           A1    20050825   CA 2005-2555248       20050216
     EP 1719509           A1    20061108   EP 2005-708114        20050216
     EP 1719509           B1    20091007
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA,
             IS, YU
     CN 101014330         A     20070808   CN 2005-80005187      20050216
     JP 2007522256        T     20070809   JP 2006-553602        20050216
     AT 444743            T     20091015   AT 2005-708114        20050216
     PT 1719509           E     20100113   PT 2005-708114        20050216
     ES 2334447           T3    20100310   ES 2005-708114        20050216
     IN 2006DN04546       A     20070810   IN 2006-DN4546        20060807
     KR 2007007783        A     20070116   KR 2006-716184        20060811
     MX 2006009295        A     20070323   MX 2006-9295          20060816
     US 20070149618       A1    20070628   US 2006-506469        20060816
     US 20080125485       A1    20080529   US 2007-839508        20070815
     US 20080293816       A1    20081127   US 2008-588166        20080807
     US 20090111779       A1    20090430   US 2008-257854        20081024
PRIORITY APPLN. INFO.:                     ES 2004-371         A  20040217
                                           WO 2005-ES70017     W  20050216
                                           US 2006-588166      A2 20060802
                                           ES 2006-2219        A  20060816
                                           US 2006-506469      A2 20060816
                                           ES 2007-1857        A  20070702
                                           US 2008-588166      A2 20080807
```

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforementioned compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases which present a reduction in apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compds. in non-quiescent

cells. In addition, the invention details the potentiating effect of said compds. on known cytostatic medicines in the treatment of tumors and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compds., based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.

IPCI A61K0031-185 [ICM,7]; A61P0035-00 [ICS,7]; A61P0017-06 [ICS,7];
     A61P0017-00 [ICS,7,C*]
IPCR A61K0031-185 [I,C*]; A61K0031-185 [I,A]; A61K0031-21 [I,C*]; A61K0031-255
     [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0035-00 [I,C*];
     A61P0035-00 [I,A]
CC   63-6 (Pharmaceuticals)
ST   dihydroxybenzenesulfonic acid drug formulation
IT   Neoplasm
       Psoriasis
        (use of dihydroxybenzenesulfonic acid in drugs for
        treatment of angiodependent diseases)
IT   88-46-0, 2,5-Dihydroxybenzenesulfonic acid   20123-80-2
     , 2,5-Dihydroxybenzenesulfonic acid calcium salt   862162-74-1
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (use of dihydroxybenzenesulfonic acid in drugs for
        treatment of angiodependent diseases)
IT   88-46-0, 2,5-Dihydroxybenzenesulfonic acid   20123-80-2
     , 2,5-Dihydroxybenzenesulfonic acid calcium salt   862162-74-1
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (use of dihydroxybenzenesulfonic acid in drugs for
        treatment of angiodependent diseases)
RN   88-46-0 HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN   20123-80-2 HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

RN   862162-74-1 HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:?) (CA INDEX
     NAME)



x K

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:521020 HCAPLUS Full-text
DOCUMENT NUMBER: 150:487712
TITLE: Methods of use 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: U.S. Pat. Appl. Publ., 32pp., Cont.-in-part of U.S. Ser. No. 588,166.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090111779	A1	20090430	US 2008-257854	20081024
ES 2238924	A1	20050901	ES 2004-371	20040217
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070149618	A1	20070628	US 2006-506469	20060816
US 20080293816	A1	20081127	US 2008-588166	20080807

PRIORITY APPLN. INFO.:

ES 2004-371	A	20040217
WO 2005-ES70017	W	20050216
US 2006-506469	A3	20060816
US 2008-588166	A2	20080807
US 2006-588166	A2	20060802

OTHER SOURCE(S): MARPAT 150:487712

GI



I

AB Methods of use 2,5-dihydroxybenzene sulfonic acid compds. of formula I, where X is a hydrogen, an organic cation or an inorg. cation; n is an integer from 1 to 2; and m is an integer from 1 to 2, for the treatment of cancer, rosacea and psoriasis are disclosed. The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for the treatment of skin cancer, organ cancer and leukemia. Method also involves in improving the efficacy of chemotherapy, radiation therapy and cancer immunotherapy. The invention also provides methods for the treatment of rosacea and psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one other therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

INCL 514167000; 514576000; 514568000; 514171000

IPCI A61K0031-59 [I,A]; A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-56 [I,A]; A61P0035-00 [I,A]; A61P0017-00 [I,A]

IPCR A61K0031-59 [I,C]; A61K0031-59 [I,A]; A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]

NCL 514/167.000; 514/171.000; 514/568.000; 514/576.000

CC 1-6 (Pharmacology)
Section cross-reference(s): 2, 63

ST dihydroxybenzene sulfonate compd steroid combination therapy cancer rosacea psoriasis; antitumor antiinflammatory antioxidant combination chemotherapy potentiation dihydroxybenzene sulfonate compd

IT Animal cell line
(C-6; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(basal cell carcinoma; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
(basal cell; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Retinoids
Steroids

```
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid
        compds. for treatment of cancer, rosacea and
        psoriasis)
IT   Antiproliferative agents
     Antitumor agents
     Brain, neoplasm
     Combination chemotherapy
     Erythema
     Human
     Leukemia
     Melanoma
     Neoplasm
     Neuroglia, neoplasm
       Pharmaceutical carriers
       Pharmaceutical creams
       Psoriasis
     Skin, neoplasm
     Telangiectasia
     Topical drug delivery systems
        (methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
IT   Hydrocarbon oils
     Petrolatum
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
IT   Drug interactions
        (potentiation; methods of use 2,5-dihydroxybenzene sulfonic acid
        compds. for treatment of cancer, rosacea and
        psoriasis)
IT   Skin, disease
        (rosacea, characterized by papules and pustules; methods of use
        2,5-dihydroxybenzene sulfonic acid compds. for treatment of
        cancer, rosacea and psoriasis)
IT   Skin, disease
        (rosacea; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
IT   Neuroglia, neoplasm
        (s.c.; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
IT   69-72-7, Salicylic acid, biological studies
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (codrug; methods of use 2,5-dihydroxybenzene sulfonic acid
        compds. for treatment of cancer, rosacea and
        psoriasis)
IT   1406-16-2D, Vitamin D, analogs
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid
        compds. for treatment of cancer, rosacea and
        psoriasis)
IT   51-21-8, 5-FU   57-22-7, Vincristine   88-46-0,
     2,5-Dihydroxybenzene sulfonic acid   2624-44-4, Diethylamine
     2,5-dihydroxybenzenesulfonate   15663-27-1, Cisplatin   20123-80-2
     , Calcium 2,5-dihydroxybenzenesulfonate   21799-87-1, Potassium
     2,5-dihydroxybenzenesulfonate   33069-62-4, Paclitaxel   97225-83-7,
     Magnesium 2,5-dihydroxybenzenesulfonate   97682-44-5, Irinotecan
     RL: PAC (Pharmacological activity); THU (Therapeutic
```

```
     use); BIOL (Biological study); USES (Uses)
        (methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
IT   112-92-5, Stearyl alcohol   36653-82-4, Cetyl alcohol
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
IT   88-46-0, 2,5-Dihydroxybenzene sulfonic acid   2624-44-4
     , Diethylamine 2,5-dihydroxybenzenesulfonate   20123-80-2,
     Calcium 2,5-dihydroxybenzenesulfonate   21799-87-1, Potassium
     2,5-dihydroxybenzenesulfonate
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
        treatment of cancer, rosacea and psoriasis)
RN   88-46-0  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-  (CA INDEX NAME)
```



```
RN   2624-44-4  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
     (CA INDEX NAME)

     CM   1

     CRN  109-89-7
     CMF  C4 H11 N
```

```
     CM   2

     CRN  88-46-0
     CMF  C6 H6 O5 S
```



```
RN   20123-80-2  HCAPLUS
```

CN   Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN   21799-87-1 HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L63 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1162068 HCAPLUS Full-text
DOCUMENT NUMBER: 149:402057
TITLE: Nitrosated derivatives of 2,5-dihydroxybenzene compounds and their preparation and use in the treatment of diseases
INVENTOR(S): Gimenez Gallego, Guillermo; Saenz De Tejada Gorman, Inigo; Cuevas Sanchez, Pedro; Angulo Frutos, Javier; Valverde Lopez, Serafin
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 147pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008113863	A2	20080925	WO 2008-EP53455	20080324
WO 2008113863	A3	20081211		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: ES 2007-764 A 20070322
ES 2007-2037 A 20070720

OTHER SOURCE(S): CASREACT 149:402057; MARPAT 149:402057

GI



I



II

AB The invention relates to nitrosated derivs. of 2,5-dihydroxybenzene compds. of formula I that are useful in the preparation of medicinal products for the treatment of different diseases. The diseases in question are, in particular: cancer, rosacea, psoriasis, fibrosis, hemangiomas, ocular diseases, skin pigmentation and skin hyperpigmentation, diseases associated with amyloidosis, dermatitis, actinic and seborrheic keratosis, erectile dysfunction, female sexual dysfunction, arterial hypertension, atherosclerosis, inflammatory diseases in particular, arthritis, glomerulonephritis and asthma, intestinal inflammatory diseases in particular, ulcerative colitis and Crohn's disease, benign prostatic hyperplasia, Leishmaniasis, angiogenesis associated to chronic temporal lobe epilepsy, pain, hyperlipidemia and thrombosis. Compds. of formula I wherein R1 is (CH2)0-6SO3H and derivs., (CH2)0-6PO3H and derivs., (CH2)0-6CO2H and derivs., CH=CH(CH2)0-6SO3H and derivs., CH=CH(CH2)0-6PO3H and derivs., and CH=CH(CH2)0-6CO2H and derivs.; R9 and R9' are independently OH and derivs. and O-acyl, with the proviso that at least one of R9 and R9' is OH derivative; and their salts, isomers, prodrugs and solvates thereof, are claimed. Example compound II was prepared by esterification of 5-bromovaleric acid with 4-nitrophenol; the resulting 5-bromovaleric acid 4-nitrophenyl ester underwent nitrosation with silver nitrate to give 5-nitrooxyvaleric acid 4-nitrophenyl ester, which underwent sulfonylation and substitution to give compound II. All the invention compds. were evaluated for their FGF-1 inhibitory activity (data given).

IPCI C07C0203-04 [I,A]; C07C0309-24 [I,A]; C07C0309-42 [I,A]; A61K0031-216 [I,A]; A61K0031-215 [I,A]; A61P0035-00 [I,A]; A61P0001-04 [I,A]; A61P0015-10 [I,A]; A61P0015-12 [I,A]; A61P0017-06 [I,A]; A61P0025-08 [I,A]; A61P0019-02 [I,A]; A61P0027-02 [I,A]; A61P0029-00 [I,A]; A61P0007-02 [I,A]; A61P0007-04 [I,A]; A61P0009-12 [I,A]; A61P0009-00 [I,C*]; C07C0203-00 [I,C]; C07C0203-04 [I,A]; A61K0031-21 [I,C]; A61K0031-215 [I,A]; A61K0031-216 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0015-00 [I,C]; A61P0015-10 [I,A]; A61P0015-12 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C]; A61P0025-08 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0309-00 [I,C]; C07C0309-24 [I,A]; C07C0309-42 [I,A]

IPCR C07C0203-00 [I,C]; C07C0203-04 [I,A]; A61K0031-21 [I,C]; A61K0031-215 [I,A]; A61K0031-216 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0015-00 [I,C]; A61P0015-10 [I,A]; A61P0015-12 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A];

```
     A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C]; A61P0025-08
     [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]; A61P0029-00 [I,C];
     A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0309-00
     [I,C]; C07C0309-24 [I,A]; C07C0309-42 [I,A]
CC   25-13 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
     Section cross-reference(s): 1, 63
ST   nitrosated dihydroxybenzenesulfonic acid prepn FGF1 inhibitor
     treatment disease
IT   Amyloidosis
        (- associated diseases, treatment of; preparation of nitrosated
        derivs. of dihydroxybenzene compds. useful in treatment and
        prophylaxis of different diseases)
IT   Animal cell line
        (3T3; preparation of nitrosated derivs. of dihydroxybenzene compds. useful
        in treatment and prophylaxis of different diseases)
IT   Keratosis
        (actinic, treatment of; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   Antiarteriosclerotics
        (antiatherosclerotics; preparation of nitrosated derivs. of dihydroxybenzene
        compds. useful in treatment and prophylaxis of different
        diseases)
IT   Prostate gland disease
        (benign hyperplasia, treatment of; preparation of nitrosated
        derivs. of dihydroxybenzene compds. useful in treatment and
        prophylaxis of different diseases)
IT   Angiogenesis
        (chronic temporal lobe epilepsy- associated, treatment of;
        preparation of nitrosated derivs. of dihydroxybenzene compds. useful in
        treatment and prophylaxis of different diseases)
IT   Antimicrobial agents
     Antioxidants
     Cholinesterase inhibitors
     Endothelin receptor antagonists
     Immunomodulators
     NMDA receptor antagonists
     Nonsteroidal anti-inflammatory drugs
        (codrugs; preparation of nitrosated derivs. of dihydroxybenzene
        compds. useful in treatment and prophylaxis of different
        diseases)
IT   Retinoids
     Steroids
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (codrugs; preparation of nitrosated derivs. of dihydroxybenzene
        compds. useful in treatment and prophylaxis of different
        diseases)
IT   Hydrolysis
        (enzymic; preparation of nitrosated derivs. of dihydroxybenzene compds.
        useful in treatment and prophylaxis of different diseases)
IT   Sexual disorders
        (female, treatment of; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   Cell proliferation
        (glioma; preparation of nitrosated derivs. of dihydroxybenzene compds.
        useful in treatment and prophylaxis of different diseases)
IT   Skin, disease
        (hyperpigmentation, treatment of; preparation of nitrosated
        derivs. of dihydroxybenzene compds. useful in treatment and
```

```
        prophylaxis of different diseases)
IT   Sexual disorders
        (impotence, treatment of; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   Tau proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (phosphorylation inhibitors, codrugs; preparation of nitrosated
        derivs. of dihydroxybenzene compds. useful in treatment and
        prophylaxis of different diseases)
IT   Analgesics
     Angiogenesis inhibitors
     Anti-inflammatory agents
     Antiarthritics
     Antiasthmatics
     Anticoagulants
     Antifibrotic agents
     Antihypertensives
     Antitumor agents
     Antiulcer agents
     Combination chemotherapy
     Cytotoxic agents
       Drugs
     Fibroblast
     Heart rate
     Hypolipemic agents
       Pharmaceutical carriers
       Pharmaceutical excipients
     Phosphorylation
       Prodrugs
     Prophylaxis
     Signal transduction
     Vasodilators
        (preparation of nitrosated derivs. of dihydroxybenzene compds. useful in
        treatment and prophylaxis of different diseases)
IT   Skin, disease
        (rosacea, treatment of; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   Keratosis
        (seborrheic, treatment of; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   Arthritis
     Asthma
     Atherosclerosis
     Crohn disease
     Dermatitis
     Eye, disease
     Fibrosis
     Glomerulonephritis
     Hemangioma
     Hyperlipidemia
     Hypertension
     Inflammation
     Neuroglia, neoplasm
     Pain
     Pigmentation disorders
       Psoriasis
     Thrombosis
     Ulcerative colitis
```

```
        (treatment of; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   69-72-7, Salicylic acid, biological studies   1406-16-2D, Vitamin D,
     analogs
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (codrugs; preparation of nitrosated derivs. of dihydroxybenzene
        compds. useful in treatment and prophylaxis of different
        diseases)
IT   1061696-45-4P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN
     (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate and intermediate; preparation of nitrosated
        derivs. of dihydroxybenzene compds. useful in treatment and
        prophylaxis of different diseases)
IT   1061696-48-7P   1061696-51-2P   1061696-54-5P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
     THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (drug candidate; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   9001-08-5
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitor, codrugs; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   9036-21-9, Cyclic nucleotide phosphodiesterase   9068-52-4, CGMP
     phosphodiesterase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitors, codrugs; preparation of nitrosated derivs. of
        dihydroxybenzene compds. useful in treatment and prophylaxis
        of different diseases)
IT   96627-32-6P   1061696-58-9P   1061696-60-3P   1061696-62-5P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of nitrosated derivs. of dihydroxybenzene compds.
        useful in treatment and prophylaxis of different diseases)
IT   7665-99-8, CGMP   10102-43-9, Nitric oxide, biological studies
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of nitrosated derivs. of dihydroxybenzene compds. useful in
        treatment and prophylaxis of different diseases)
IT   100-02-7, 4-Nitrophenol, reactions   2067-33-6, 5-Bromovaleric acid
     20123-80-2, Calcium dobesilate   21799-87-1
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (starting material; preparation of nitrosated derivs. of dihydroxybenzene
        compds. useful in treatment and prophylaxis of different
        diseases)
IT   20123-80-2, Calcium dobesilate   21799-87-1
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (starting material; preparation of nitrosated derivs. of dihydroxybenzene
        compds. useful in treatment and prophylaxis of different
        diseases)
RN   20123-80-2  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1)  (CA INDEX NAME)
```



● 1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L63 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:223400 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276783
TITLE: 2,5-Dihydroxybenzene for the treatment of psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 66pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020030	A1	20080221	WO 2007-EP58443	20070815

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,

```
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
     ES 2315118          A1    20090316    ES 2006-2218          20060816
     ES 2315118          B1    20091230
     US 20080113947      A1    20080515    US 2007-839515        20070815
     US 20080113948      A1    20080515    US 2007-839520        20070815
     US 20080114060      A1    20080515    US 2007-839522        20070815
     US 20080125486      A1    20080529    US 2007-839525        20070815
     EP 2056814          A1    20090513    EP 2007-788429        20070815
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
             AL, BA, HR, MK, RS
     MX 2009001660       A     20090424    MX 2009-1660          20090213
PRIORITY APPLN. INFO.:                     ES 2006-2218        A 20060816
                                           ES 2007-1856        A 20070702
                                           WO 2007-EP58443     W 20070815
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):         MARPAT 148:276783
```

AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a medicinal product for the treatment and/or prophylaxis of psoriasis. IPCI A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-21 [I,A]; A61K0031-216 [I,A]; A61K0031-255 [I,A]; A61P0017-06 [I,A]; A61P0017-00 [I,C*]; A61K0031-60 [I,A]; A61K0045-06 [I,A]; A61K0045-00 [I,C*]

IPCR A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-21 [I,C]; A61K0031-21 [I,A]; A61K0031-216 [I,A]; A61K0031-255 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A]

CC 1-12 (Pharmacology)

ST hydroxybenzene deriv psoriasis therapy

IT Epidermal growth factor receptors
Fibroblast growth factor receptors
Hepatocyte growth factor
Hepatocyte growth factor receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene derivs. for treatment of psoriasis)

IT Therapy
(coadjuvant; hydroxybenzene derivs. for treatment of psoriasis)

IT Angiogenesis inhibitors
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antitumor agents
Apoptosis
Buccal drug delivery systems
Endothelin receptor antagonists
Fibrosis
Human
Immunomodulators
Lung, neoplasm
Neuroglia, neoplasm
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Photodynamic therapy
Phototherapy
Prodrugs
Prophylaxis

```
     Prostate gland, neoplasm
       Psoriasis
     Rectal drug delivery systems
     Topical drug delivery systems
     Transdermal drug delivery systems
        (hydroxybenzene derivs. for treatment of psoriasis)
IT   Corticosteroids, biological studies
     Retinoids
     Steroids, biological studies
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (hydroxybenzene derivs. for treatment of psoriasis)
IT   Fibroblast
        (mitogenesis; hydroxybenzene derivs. for treatment of
        psoriasis)
IT   62031-54-3, Fibroblast growth factor   62229-50-9, Epidermal growth factor
     127464-60-2, Vascular endothelial growth factor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (antagonists; hydroxybenzene derivs. for treatment of
        psoriasis)
IT   106096-92-8, FGF-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hydroxybenzene derivs. for treatment of psoriasis)
IT   59-05-2, Methotrexate   69-72-7, Salicylic acid, biological studies
     88-46-0, 2,5-Dihydroxybenzenesulfonic acid   110-17-8D,
     2-Butenedioic acid (2E)-, derivs.   123-31-9D, 1,4-Dihydroxybenzene,
     derivs.   490-79-9, Gentisic acid   636-01-1, 2,5-Dihydroxycinnamic acid
     1406-16-2D, Vitamin D, analogs   21799-87-1, Potassium
     2,5-Dihydroxybenzenesulfonate   21799-87-1D, ester derivs.
     51579-69-2   57775-26-5   59687-22-8   59865-13-3, Cyclosporin
     60630-38-8   79122-68-2   159252-66-1   159252-66-1D, ester derivs.
     170277-31-3, Infliximab   185243-69-0, Etanercept   214745-43-4,
     Efalizumab   222535-22-0, Alefacept   331731-18-1, Adalimumab
     748106-93-6   1007839-71-5   1007839-72-6D, ester derivs.   1007839-87-3
     1007839-89-5   1007839-91-9   1007839-93-1   1007839-94-2   1007839-96-4
     1007840-16-5   1007840-17-6   1007840-18-7   1007840-19-8   1007840-20-1
     1007840-21-2   1007840-22-3   1007840-23-4   1007840-24-5   1007849-27-5
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (hydroxybenzene derivs. for treatment of psoriasis)
IT   80449-02-1, Protein tyrosine kinase   141436-78-4, Protein kinase C
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitors; hydroxybenzene derivs. for treatment of
        psoriasis)
IT   88-46-0, 2,5-Dihydroxybenzenesulfonic acid   21799-87-1
     , Potassium 2,5-Dihydroxybenzenesulfonate   21799-87-1D, ester
     derivs.
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (hydroxybenzene derivs. for treatment of psoriasis)
RN   88-46-0  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-  (CA INDEX NAME)
```



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:705929 HCAPLUS Full-text
DOCUMENT NUMBER: 147:87646
TITLE: 2,5-Dihydroxybenzene sulfonate compounds for treatment of cancer, rosacea, and psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S. Ser. No. 588,166.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     US 20070149618       A1    20070628   US 2006-506469         20060816
     ES 2238924           A1    20050901   ES 2004-371            20040217
     ES 2238924           B1    20061201
     WO 2005077352        A1    20050825   WO 2005-ES70017        20050216
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     US 20080125485       A1    20080529   US 2007-839508         20070815
     US 20090111779       A1    20090430   US 2008-257854         20081024
PRIORITY APPLN. INFO.:                     ES 2004-371         A  20040217
                                           WO 2005-ES70017     W  20050216
                                           US 2006-588166      A2 20060802
                                           ES 2006-2219        A  20060816
                                           US 2006-506469      A2 20060816
                                           ES 2007-1857        A  20070702
                                           US 2008-588166      A2 20080807
```

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compns. comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. Administration of 2,5-dihydroxybenzene sulfonate combined with irinotecan reduced the tumor progression of gliomas in rats to a greater degree than treatment of either agent alone.

INCL 514553000; 514171000; 514559000; 514167000; 514159000

IPCI A61K0031-185 [I,A]; A61K0031-60 [I,A]; A61K0031-59 [I,A]; A61K0031-56 [I,A]

IPCR A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61K0031-59 [I,C]; A61K0031-59 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]

NCL 514/553.000; 514/159.000; 514/167.000; 514/171.000; 514/559.000

CC 1-6 (Pharmacology)

ST dihydroxybenzene sulfonate cancer rosacea psoriasis therapy; glioma irinotecan dihydroxybenzene sulfonate antitumor combination

IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Buccal drug delivery systems
Chemosensitizers, pharmaceutical
  Chemotherapy
Combination chemotherapy
Cytotoxic agents

```
      Dermatological agents
      Immunomodulators
      Inhalation drug delivery systems
      Leukemia
      Melanoma
      NMDA receptor antagonists
      Neuroglia, neoplasm
      Oral drug delivery systems
      Parenteral drug delivery systems
        Pharmaceutical carriers
        Pharmaceutical creams
      Proliferation inhibition
        Psoriasis
      Rectal drug delivery systems
      Skin, neoplasm
      Topical drug delivery systems
         (2,5-dihydroxybenzene sulfonate compds. for treatment of
         cancer, rosacea and psoriasis)
IT    Retinoids
      Steroids
      RL: PAC (Pharmacological activity); THU (Therapeutic
      use); BIOL (Biological study); USES (Uses)
         (2,5-dihydroxybenzene sulfonate compds. for treatment of
         cancer, rosacea and psoriasis)
IT    Petrolatum
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (2,5-dihydroxybenzene sulfonate compds. for treatment of
         cancer, rosacea and psoriasis)
IT    Carcinoma
      Skin, neoplasm
         (Bowen's disease, verrucae; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Keratosis
         (actinic; 2,5-dihydroxybenzene sulfonate compds. for treatment
         of cancer, rosacea and psoriasis)
IT    Apoptosis
         (basal cell carcinoma cells; 2,5-dihydroxybenzenesulfonate-induced;
         2,5-dihydroxybenzene sulfonate compds. for treatment of
         cancer, rosacea and psoriasis)
IT    Skin, neoplasm
         (basal cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Carcinoma
         (basal cell; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Carcinoma
         (cutaneous squamous cell; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Antitumor agents
        Immunotherapy
        Radiotherapy
         (efficacy; agents improving; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Skin, neoplasm
         (keratoacanthoma; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Sarcoma
         (orangiosarcoma; 2,5-dihydroxybenzene sulfonate compds. for
         treatment of cancer, rosacea and psoriasis)
IT    Drug interactions
         (pharmacodynamic, potentiation; 2,5-dihydroxybenzene
```

```
        sulfonate compds. for treatment of cancer, rosacea and
        psoriasis)
IT   Skin, disease
        (rosacea; 2,5-dihydroxybenzene sulfonate compds. for treatment
        of cancer, rosacea and psoriasis)
IT   Neoplasm
        (solid; 2,5-dihydroxybenzene sulfonate compds. for treatment
        of cancer, rosacea and psoriasis)
IT   Skin, neoplasm
        (squamous cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for
        treatment of cancer, rosacea and psoriasis)
IT   Paraffin waxes
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (white soft; 2,5-dihydroxybenzene sulfonate compds. for
        treatment of cancer, rosacea and psoriasis)
IT   51-21-8, 5-Fluorouracil   57-22-7, Vincristine   69-72-7, Salicylic acid,
     biological studies   88-46-0, 2,5-Dihydroxybenzenesulfonic acid
     1406-16-2D, Vitamin D, analog   2624-44-4, Diethylamine
     2,5-dihydroxybenzenesulfonate   15663-27-1, Cisplatin   20123-80-2
     , Calcium 2,5-dihydroxybenzenesulfonate   21799-87-1, Potassium
     2,5-dihydroxybenzenesulfonate   33069-62-4, Paclitaxel
     68864-98-2, 2,5-Dihydroxybenzenesulfonate   97225-83-7, Magnesium
     2,5-dihydroxybenzenesulfonate   97682-44-5, Irinotecan   100286-90-6,
     Campto
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (2,5-dihydroxybenzene sulfonate compds. for treatment of
        cancer, rosacea and psoriasis)
IT   112-92-5, Stearic alcohol   7732-18-5, Water, biological studies
     36653-82-4, Cetylic alcohol   942134-54-5, Sorbinate deato
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (2,5-dihydroxybenzene sulfonate compds. for treatment of
        cancer, rosacea and psoriasis)
IT   116243-73-3, Endothelin
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (antagonist; 2,5-dihydroxybenzene sulfonate compds. for
        treatment of cancer, rosacea and psoriasis)
IT   88-46-0, 2,5-Dihydroxybenzenesulfonic acid   2624-44-4
     , Diethylamine 2,5-dihydroxybenzenesulfonate   20123-80-2,
     Calcium 2,5-dihydroxybenzenesulfonate   21799-87-1, Potassium
     2,5-dihydroxybenzenesulfonate   68864-98-2,
     2,5-Dihydroxybenzenesulfonate
     RL: PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (2,5-dihydroxybenzene sulfonate compds. for treatment of
        cancer, rosacea and psoriasis)
RN   88-46-0  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-  (CA INDEX NAME)
```




```
RN   2624-44-4  HCAPLUS
```

CN   Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
     (CA INDEX NAME)

CM   1

CRN 109-89-7
CMF C4 H11 N

$H_3C-CH_2-NH-CH_2-CH_3$

CM   2

CRN 88-46-0
CMF C6 H6 O5 S



RN   20123-80-2 HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



RN   21799-87-1 HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX
     NAME)



```
RN   68864-98-2  HCAPLUS
CN   Benzenesulfonic acid, 2,5-dihydroxy-, ion(1-)  (CA INDEX NAME)
```



```
L63  ANSWER 7 OF 8  WPIX COPYRIGHT 2010       THOMSON REUTERS on STN
ACCESSION NUMBER:     2008-N22597 [200877]   WPIX
TITLE:                New cinnamic amide derivative useful for treating
                      diseases responsive to modulation of potassium channel,
                      e.g., respiratory diseases, convulsion, erectile
                      dysfunction, gastrointestinal dysfunction, ischemia,
                      schizophrenia and sleep disorder
DERWENT CLASS:        B05
INVENTOR:             CHRISTOPHERSEN P; DEMNITZ J; GRUNNET M; JENSEN T; JENSEN
                      T D; JONES D; JONES D S; MADSEN L; MADSEN L S; NARDI A;
                      NIELSEN E; NIELSEN E O; STROBAK D; STROBAEK D
PATENT ASSIGNEE:      (NURO-C) NEUROSEARCH AS
COUNTRY COUNT:        121

PATENT INFO ABBR.:

      PATENT NO      KIND DATE     WEEK     LA  PG          MAIN IPC
      ----------------------------------------------------------------
      WO 2008074755   A2 20080626 (200877)* EN  45[1]
      WO 2008074755   A3 20081002 (200877)  EN
      EP 2121569      A2 20091125 (200978)  EN
      US 20100087496  A1 20100408 (201024)  EN
      JP 2010513387   W  20100430 (201029)  JA  47

APPLICATION DETAILS:

      PATENT NO      KIND                  APPLICATION    DATE
      -----------------------------------------------------------------
      WO 2008074755 A2                     WO 2007-EP64015 20071217
      US 20100087496 A1 Provisional        US 2006-870781P 20061219
      EP 2121569 A2                        EP 2007-857649 20071217
```

EP 2121569 A2 PCT Application WO 2007-EP64015 20071217
US 20100087496 A1 PCT Application WO 2007-EP64015 20071217
US 20100087496 A1 US 2009-519683 20090724
JP 2010513387 W PCT Application WO 2007-EP64015 20071217
JP 2010513387 W JP 2009-542019 20071217

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 2121569	A2	Based on	WO 2008074755	A
JP 2010513387	W	Based on	WO 2008074755	A

PRIORITY APPLN. INFO: DK 2007-481 20070328
DK 2006-1657 20061218
US 2006-870781P 20061219

AB WO 2008074755 A2 UPAB: 20091126

NOVELTY - A cinnamic amide derivative (I), is new.

DETAILED DESCRIPTION - A cinnamic amide derivative of formula (I), or its enantiomer, mixture of its enantiomers, or salt, is new.

R1=nitro, amino, hydroxy, carboxy, sulfonic acid, sulfonic acid alkyl ester, sulfamoyl, acetamido, methyl-sulfonyl-amino, phenyl-sulfonyl-amino, N-methyl-sulfonyl-carboxamide (methyl-sulfonyl-amino-carbonyl), N-phenyl-sulfonyl-carboxamide (phenyl-sulfonyl-amino-carbonyl), trifluoromethyl-sulfonyl-amino, trifluoromethyl-acetyl-amino, 2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl- ethyl, tetrazolyl, tetrazolyl-methoxy, 5-oxo-4,5-dihydro-(1,2,4)oxadiazol-3-yl or N-cyano-carboxamide;

R2 and R3=phenyl (optionally substituted with halo and/or trifluoromethyl), H, halo, trifluoromethyl, or hydroxy;

R4 and R5=H, halo, trifluoromethyl, nitro and/or phenyl;or

R4 and R5 together with the aromatic ring to which they are attached=benzo-fused carbocyclic aromatic ring;

R' and R'a=H;or

R' and R'a together with the carbon atoms of the aromatic ring to which they are attached=bicyclic carbocyclic or heterocyclic ring selected from 2H-chromenyl (optionally substituted with oxo to form a 2-oxo-2H-chromenyl derivative), or indolyl.

INDEPENDENT CLAIMS are included for the following:

(1) use of a combination of a cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; or their salts, for the manufacture of a medicament for the treatment or alleviation of sexual dysfunction; and

(2) a kit of parts comprising at least two separate unit dosage forms cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; and optionally instructions for the simultaneous, sequential or separate administration of the cinnamic amide derivative (I), and the phosphodiesterase inhibitor, or the agent, to a patient.

ACTIVITY - Respiratory-Gen.; Anticonvulsant; Vasotropic; Cardiant; CNS-Gen.; Muscular-Gen.; Nephrotropic; Uropathic; Hepatotropic; Gastrointestinal-Gen.; Laxative; Antidiarrheic; Cerebroprotective; Vulnerary; Antianginal; Antiparkinsonian; Neuroleptic; Nootropic; Tranquilizer; Antidepressant; Antimanic; Neuroprotective; Analgesic; Gynecological; Hypnotic; Immunosuppressive; Antiarrhythmic; Cardiovascular-Gen.; Hypotensive; Relaxant; Antidiabetic; Tocolytic; Cytostatic; Antiinflammatory; Auditory; Antimigraine; Endocrine-gen.; Ophthalmological; Osteopathic; Angiogenesis-inhibitor; Antiarthritic; Antirheumatic; Antipsoriatic; Antianemic.

MECHANISM OF ACTION - Ion channel modulator e.g. calcium activated potassium (BK) channel modulator. (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)- phenyl)-3-naphthalen-2-yl-acrylamide (I') was tested for BK channel opening activity using BK channels heterologously expressed in Xenopus laevis oocytes in terms of current. BK current

was activated by repeated step protocols. The compound (I') (1 mu M) was added. The compound (I') showed marked increased in current of 6-9 mu M at 80-134 seconds.

USE - In the manufacture of a pharmaceutical composition/medicament for treating respiratory disease, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, motor neuron diseases, myokymia, renal disorders, polycystic kidney disease, bladder hyperexcitability, bladder spasms, urinogenital disorders, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, gastrointestinal hypomotility disorders, gastrointestinal motility insufficiency, postoperative ileus, constipation, gastroesophageal reflux disorder, secretory diarrhea, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, ataxia, traumatic brain injury, stroke, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, autism, anxiety, mood disorders, depression, manic depression, psychotic disorders, dementia, learning deficiencies, age related memory loss, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, sleeping disorders, sleep apnea, Raynaud's disease, intermittent claudication, Sjogren's syndrome, xerostomia, arrhythmia, cardiovascular disorders, hypertension, myotonic dystrophy, myotonic muscle dystrophia, spasticity, xerostomia, diabetes Type II, hyperinsulinemia, premature labor, cancer, brain tumors, inflammatory bowel disease, irritable bowel syndrome, colitis, colitis Crohn', immune suppression, hearing loss, migraine, pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, vision loss, rhinorrhoea, ocular hypertension (glaucoma), baldness, cardiac arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, tachyarrhythmia, atrial tachyarrhythmia, ventricular tachyarrhythmia, bradyarrhythmia, or any other abnormal rhythm, e.g. caused by myocardial ischemia, myocardial infarction, cardiac hypertrophy or cardiomyopathy disease/disorder/condition responsive to modulation of potassium channel in a mammal including a human, and for treating sexual dysfunction i.e. male dysfunction and female dysfunction (claimed); and also for treating diseases such as bone metabolic disease, disease that is responsive to inhibition of angiogenesis, an ophthalmic angiogenesis related diseases, rheumatoid arthritis, psoriasis and sickle-cell anemia, and pain.

ADVANTAGE - The compound are potent ion channel modulator and treats disease, disorder or condition responsive to modulation of potassium channels without any harmful side effects. The compounds show calcium activated potassium channel opening activity in sub-micromolar and micromolar range, i.e., from below 1-100 mu M.

AN.S DCR-89832
CN.P CALCIUM DOBESILATE
CN.S Calcium; 2,5-dihydroxy-benzenesulfonate
SDCN R20556

CM 1

Ca

CM 2



```
L63  ANSWER 8 OF 8  WPIX COPYRIGHT 2010       THOMSON REUTERS on STN
ACCESSION NUMBER:      1996-020345 [199602]   WPIX
DOC. NO. CPI:          C1996-006976 [199602]
TITLE:                 Opiate antagonist and calcium salt in compsn.  - for
                       treatment of endorphin-mediated pathologies
DERWENT CLASS:         B05; C03
INVENTOR:              CIORCI R L; MINOIA P; SCIORSCI R L
PATENT ASSIGNEE:       (CIOR-I) CIORCI R L; (MINO-I) MINOIA P; (RAPH-I) RAPHAEL
                       L G; (SCIO-I) SCIORSCI R; (SCIO-I) SCIORSCI R L; (EXCE-N)
                       EXCELSIOR LIFE SCI IRELAND LTD
COUNTRY COUNT:         64

PATENT INFO ABBR.:

      PATENT NO      KIND DATE     WEEK     LA  PG          MAIN IPC
      ----------------------------------------------------------------
      WO 9531985      A2 19951130 (199602)* EN  19[0]
      AU 9526149      A  19951218 (199611)  EN
      WO 9531985      A3 19960104 (199622)  EN
      EP 760661       A1 19970312 (199715)  EN  [0]
      IT 1269826      B  19970415 (199744)  IT
      JP 10500423     W  19980113 (199812)  JA  19[0]
      KR 97703148     A  19970703 (199829)  KO
      US 5811451      A  19980922 (199845)  EN
      HU 77920        T  19981028 (199850)  HU
      EP 760661       B1 19981230 (199905)  EN
      DE 69507029     E  19990211 (199912)  DE
      ES 2128735      T3 19990516 (199926)  ES
      AU 708778       B  19990812 (199944)  EN
      CN 1151116      A  19970604 (200131)  ZH
      CN 1083264      C  20020424 (200519)  ZH
      JP 2007210995   A  20070823 (200757)  JA  11
      CA 2190943      C  20100622 (201045)  EN

APPLICATION DETAILS:

      PATENT NO      KIND                  APPLICATION    DATE
      -----------------------------------------------------------------
      WO 9531985 A2                        WO 1995-EP1931 19950522
      IT 1269826 B                         IT 1994-MI1048 19940524
      AU 9526149 A                         AU 1995-26149 19950522
      AU 708778 B                          AU 1995-26149 19950522
      CN 1151116 A                         CN 1995-193758 19950522
      CN 1083264 C                         CN 1995-193758 19950522
      DE 69507029 E                        DE 1995-69507029 19950522
      EP 760661 A1                         EP 1995-920851 19950522
      EP 760661 B1                         EP 1995-920851 19950522
      DE 69507029 E                        EP 1995-920851 19950522
      ES 2128735 T3                        EP 1995-920851 19950522
      JP 10500423 W                        JP 1995-530058 19950522
      JP 2007210995 A Div Ex               JP 1995-530058 19950522
      WO 9531985 A3                        WO 1995-EP1931 19950522
      EP 760661 A1                         WO 1995-EP1931 19950522
      JP 10500423 W                        WO 1995-EP1931 19950522
      KR 97703148 A                        WO 1995-EP1931 19950522
      US 5811451 A                         WO 1995-EP1931 19950522
      HU 77920 T                           WO 1995-EP1931 19950522
      EP 760661 B1                         WO 1995-EP1931 19950522
      DE 69507029 E                        WO 1995-EP1931 19950522
```

HU 77920 T	HU 1996-3228 19950522
KR 97703148 A	KR 1996-706602 19961121
US 5811451 A	US 1996-737902 19961121
JP 2007210995 A	JP 2006-303392 20061108
CA 2190943 C	CA 1995-2190943 19950522
CA 2190943 C PCT Application	WO 1995-EP1931 19950522

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 708778	B	Previous Publ	AU 9526149	A
DE 69507029	E	Based on	EP 760661	A
ES 2128735	T3	Based on	EP 760661	A
AU 9526149	A	Based on	WO 9531985	A
EP 760661	A1	Based on	WO 9531985	A
JP 10500423	W	Based on	WO 9531985	A
KR 97703148	A	Based on	WO 9531985	A
US 5811451	A	Based on	WO 9531985	A
HU 77920	T	Based on	WO 9531985	A
EP 760661	B1	Based on	WO 9531985	A
DE 69507029	E	Based on	WO 9531985	A
AU 708778	B	Based on	WO 9531985	A
CA 2190943	C	Based on	WO 9531985	A

PRIORITY APPLN. INFO: IT 1994-MI1048 19940524

AB WO 1995031985 A2 UPAB: 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

AN.S DCR-89832
CN.P CALCIUM DOBESILATE
CN.S Calcium; 2,5-dihydroxy-benzenesulfonate
SDCN R20556

CM 1

Ca

CM 2



SEARCH HISTORY

```
     FILE 'HCAPLUS' ENTERED AT 16:42:29 ON 22 JUL 2010
                E US2008-588166/APPS
L1            3 SEA SPE=ON  ABB=ON  PLU=ON  US2008-588166/APPS
                D SCAN

     FILE 'REGISTRY' ENTERED AT 16:43:18 ON 22 JUL 2010
L2              STRUCTURE UPLOADED
                D
L3           23 SEA SSS SAM L2
L4          575 SEA SSS FUL L2
L5              STRUCTURE UPLOADED
                D
L6           23 SEA SUB=L4 SSS SAM L5
L7          569 SEA SUB=L4 SSS FUL L5

     FILE 'HCAPLUS' ENTERED AT 16:47:38 ON 22 JUL 2010
L8         1313 SEA SPE=ON  ABB=ON  PLU=ON  L7
L9        21558 SEA SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT/CT OR (?PSORIASIS?
                OR ?PUSTULOSIS?)/BI
L10           6 SEA SPE=ON  ABB=ON  PLU=ON  L8 AND L9
L11         553 SEA SPE=ON  ABB=ON  PLU=ON  L8 AND ((BAC OR DMA OR PAC OR PKT
                OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR ?TREAT?)/BI)
L12           6 SEA SPE=ON  ABB=ON  PLU=ON  L11 AND L9
L13           6 SEA SPE=ON  ABB=ON  PLU=ON  L10 OR L12

     FILE 'REGISTRY' ENTERED AT 16:54:16 ON 22 JUL 2010
L14           1 SEA SPE=ON  ABB=ON  PLU=ON  "2,5-DIHYDROXYBENZENESULFONIC
                ACID"/CN

     FILE 'HCAPLUS' ENTERED AT 16:58:43 ON 22 JUL 2010
L15         181 SEA SPE=ON  ABB=ON  PLU=ON  L14
L16          68 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND ((BAC OR DMA OR PAC OR PKT
                OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR ?TREAT?)/BI)
L17           5 SEA SPE=ON  ABB=ON  PLU=ON  L16 AND L9
L18           6 SEA SPE=ON  ABB=ON  PLU=ON  L13 OR L17

     FILE 'REGISTRY' ENTERED AT 16:59:51 ON 22 JUL 2010
                E "2,5-DIHYDROXYBENZENESULFONIC ACID"/CN
L19           4 SEA SPE=ON  ABB=ON  PLU=ON  ("2,5-DIHYDROXYBENZENESULFONIC
                ACID CALCIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                DIETHYLAMINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                MONOSODIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                MONOTOSYLATE MORPHOLINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFON
                IC ACID SODIUM SALT"/CN)

     FILE 'HCAPLUS' ENTERED AT 17:00:36 ON 22 JUL 2010
L20         494 SEA SPE=ON  ABB=ON  PLU=ON  L19
L21         359 SEA SPE=ON  ABB=ON  PLU=ON  L20 AND ((BAC OR DMA OR PAC OR PKT
                OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR ?TREAT?)/BI)
L22           4 SEA SPE=ON  ABB=ON  PLU=ON  L21 AND L9
L23           6 SEA SPE=ON  ABB=ON  PLU=ON  L22 OR L18
L24        2346 SEA SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L25         205 SEA SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L26          71 SEA SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L27        2879 SEA SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L28           1 SEA SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L29           0 SEA SPE=ON  ABB=ON  PLU=ON  L23 AND ((L24 OR L25 OR L26 OR L27
```

```
                 OR L28))
L30            3 SEA SPE=ON  ABB=ON  PLU=ON  L1 AND L23
L31            0 SEA SPE=ON  ABB=ON  PLU=ON  L8 AND ((L24 OR L25 OR L26 OR L27
                 OR L28))
L32            0 SEA SPE=ON  ABB=ON  PLU=ON  L24 AND L25 AND L26 AND L27 AND
                 L28
L33            5 SEA SPE=ON  ABB=ON  PLU=ON  L24 AND ((L25 OR L26 OR L27 OR
                 L28))
L34            0 SEA SPE=ON  ABB=ON  PLU=ON  L25 AND ((L26 OR L27 OR L28))
L35            0 SEA SPE=ON  ABB=ON  PLU=ON  L26 AND ((L27 OR L28))
L36            0 SEA SPE=ON  ABB=ON  PLU=ON  L27 AND L28
                 D SCAN L33 TI

     FILE 'WPIX' ENTERED AT 17:06:19 ON 22 JUL 2010
L37            4 SEA SSS SAM L5
L38           31 SEA SSS FUL L5
L39           99 SEA SPE=ON  ABB=ON  PLU=ON  L38/DCR
L40            4 SEA SPE=ON  ABB=ON  PLU=ON  L39 AND (?PSORIASIS? OR ?PUSTULOSIS
                 ?)
L41          113 SEA SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L42           21 SEA SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L43           13 SEA SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L44          142 SEA SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L45            8 SEA SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L46            0 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND ((L41 OR L42 OR L43 OR L44
                 OR L45))
L47            0 SEA SPE=ON  ABB=ON  PLU=ON  L41 AND L42 AND L43 AND L44 AND
                 L45
L48            2 SEA SPE=ON  ABB=ON  PLU=ON  L41 AND ((L42 OR L43 OR L44 OR
                 L45))
L49            1 SEA SPE=ON  ABB=ON  PLU=ON  L42 AND ((L43 OR L44 OR L45))
L50            1 SEA SPE=ON  ABB=ON  PLU=ON  L43 AND ((L44 OR L45))
L51            0 SEA SPE=ON  ABB=ON  PLU=ON  L44 AND L45
L52            2 SEA SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50)

     FILE 'BEILSTEIN' ENTERED AT 17:11:11 ON 22 JUL 2010
L53            6 SEA SSS SAM L5
L54          137 SEA SSS FUL L5
L55           17 SEA SPE=ON  ABB=ON  PLU=ON  L54 AND BABSAN/FA
                 SEL BABSAN L55

     FILE 'BABS' ENTERED AT 17:12:38 ON 22 JUL 2010
L56           34 SEA SPE=ON  ABB=ON  PLU=ON  (5779456/BABSAN OR 5795277/BABSAN
                 OR 5824898/BABSAN OR 5514361/BABSAN OR 5640811/BABSAN OR
                 5663724/BABSAN OR 5513340/BABSAN OR 5650706/BABSAN OR 5661677/B
                 ABSAN OR 5664312/BABSAN OR 5683633/BABSAN OR 5716795/BABSAN OR
                 5720015/BABSAN OR 5721112/BABSAN OR 5729262/BABSAN OR 5735774/B
                 ABSAN OR 5742821/BABSAN OR 5795962/BABSAN OR 5821526/BABSAN OR
                 5823978/BABSAN OR 5833257/BABSAN OR 5834887/BABSAN OR 5864226/B
                 ABSAN OR 5883193/BABSAN OR 6272676/BABSAN OR 6307749/BABSAN OR
                 6456010/BABSAN OR 6467490/BABSAN OR 6487461/BABSAN OR 6491941/B
                 ABSAN OR 6536509/BABSAN OR 6574272/BABSAN OR 6575150/BABSAN OR
                 6607291/BABSAN OR 6649109/BABSAN)
L57            0 SEA SPE=ON  ABB=ON  PLU=ON  L56 AND (PSORIASIS? OR PUSTULOSIS?)

     FILE 'BEILSTEIN' ENTERED AT 17:16:22 ON 22 JUL 2010
L58          120 SEA SPE=ON  ABB=ON  PLU=ON  L54 NOT L55
L59           67 SEA SPE=ON  ABB=ON  PLU=ON  L58 AND (PRY<=2004 OR AY<=2004 OR
                 PY<=2004 OR PD<=2004)
                 D IDE
```

```
     FILE 'REGISTRY' ENTERED AT 17:21:41 ON 22 JUL 2010

     FILE 'HCAPLUS' ENTERED AT 17:21:44 ON 22 JUL 2010
                D STAT QUE L33

     FILE 'WPIX' ENTERED AT 17:21:54 ON 22 JUL 2010
                D STAT QUE L52

     FILE 'HCAPLUS, WPIX' ENTERED AT 17:22:10 ON 22 JUL 2010
L60           7 DUP REMOVE L33 L52 (0 DUPLICATES REMOVED)
                     ANSWERS '1-5' FROM FILE HCAPLUS
                     ANSWERS '6-7' FROM FILE WPIX
                D L60 IBIB ABS HITIND HITSTR 1-5
                D L60 IBIB AB HITSTR 6-7

     FILE 'HCAPLUS' ENTERED AT 17:22:51 ON 22 JUL 2010
                D STAT QUE L23
L61           6 SEA SPE=ON  ABB=ON  PLU=ON  L23 NOT L33

     FILE 'WPIX' ENTERED AT 17:23:02 ON 22 JUL 2010
                D STAT QUE L40
L62           4 SEA SPE=ON  ABB=ON  PLU=ON  L40 NOT L52

     FILE 'HCAPLUS, WPIX' ENTERED AT 17:23:38 ON 22 JUL 2010
L63           8 DUP REMOVE L61 L62 (2 DUPLICATES REMOVED)
                     ANSWERS '1-6' FROM FILE HCAPLUS
                     ANSWERS '7-8' FROM FILE WPIX
                D L63 IBIB ABS HITIND HITSTR 1-6
                D L63 IBIB AB HITSTR 7-8

=>


Uploading 10588166.str
```




```
chain nodes :
7  8  9  10  11  12
ring nodes :
1  2  3  4  5  6
chain bonds :
1-12  4-11  6-7  7-8  7-9  7-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  1-12  2-3  3-4  4-5  4-11  5-6  6-7  7-8  7-9  7-10


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS
```

Uploading LL5.str



chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-12 4-11 6-7 7-8 7-9 7-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-12 4-11 6-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-9 7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS